Predictive value of nodule size and differentiation in HCC recurrence after liver transplantation

Guerrini, Gian Piero; Pinelli, D.; Benedetto, Fabrizio Di; Marini, Elena; Corno, V.; Guizzetti, M.; Aluffi, A.; Zambelli, M.; Fagiuoli, Stefano; Lucà, Maria Grazia; Lucianetti, A.; Colledan, M.

doi:10.1016/j.suronc.2015.09.003

Cited by 33 publications

(21 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, the multivariate analysis remained only with undifferentiated tumor grading significant with regard to the outcome, whereas there was no significant influence of vascular invasion, primary tumor staging or the number of tumor nodules, respectively, or maximum tumor diameter neither in the pretransplant nor in the posttransplant diagnostic. These data are in accordance with other studies indicating a significant influence of poorly differentiated HCC on recurrence [17–19]. Likewise, the Toronto group recommended the appropriate impact of poorly differentiated HCC; therefore patients with advanced tumor (no restrictions on tumor size or number, only exclusion of extrahepatic disease) were considered for LT in case of good or moderate differentiated tumor, after exclusion of poorly differentiated HCC by pretransplant biopsy.…”

Section: Discussionsupporting

confidence: 86%

Accuracy of Pretransplant Imaging Diagnostic for Hepatocellular Carcinoma: A Retrospective German Multicenter Study

Herden

Schoening

Pratschke

et al. 2019

Canadian Journal of Gastroenterology and Hepatology

View full text Add to dashboard Cite

Selection and prioritization of patients with HCC for LT are based on pretransplant imaging diagnostic, taking the risk of incorrect diagnosis. According to the German waitlist guidelines, imaging has to be reported to the allocation organization (Eurotransplant) and pathology reports have to be submitted thereafter. In order to assess current procedures we performed a retrospective multicenter analysis in all German transplant centers with focus on accuracy of imaging diagnostic and tumor classification. 1168 primary LT for HCC were conducted between 2007 and 2013 in Germany. Patients inside the Milan, UCSF, and up-to-seven criteria were misclassified with definitive histologic results in 18%, 15%, and 11%, respectively. Patients pretransplant outside the Milan, UCSF, and up-to-seven criteria were otherwise misclassified in 34%, 43%, and 41%. Recurrence-free survival correlated with classification by posttransplant histological report, but not pretransplant imaging diagnostic. Univariate analysis revealed tumor size, vascular invasion, and grading as significant parameters for outcome, while tumor grading was the only parameter persisting by multivariate testing.Conclusion. There was a relevant percentage (15-40%) of patients misclassified by imaging diagnosis at a time prior to LI-RADS and guidelines to improve imaging of HCC. Outcome analysis showed a good correlation to histological, in contrast poor correlation to imaging diagnosis, suggesting an adjustment of the LT selection and prioritization criteria.

show abstract

Section: Discussionsupporting

confidence: 86%

Accuracy of Pretransplant Imaging Diagnostic for Hepatocellular Carcinoma: A Retrospective German Multicenter Study

Herden

Schoening

Pratschke

et al. 2019

Canadian Journal of Gastroenterology and Hepatology

View full text Add to dashboard Cite

show abstract

“…Postoperative pathologic tumor differentiation is another independent risk factor for prognosis (Gugenheim et al, 2013;Guerrini et al, 2015;Varona et al, 2015). The higher the histological grade of the tumor is, the poorer the prognosis of LT recipients is.…”

Section: Univariate and Multivariate Analyses Of The Prognosis Of LIVmentioning

confidence: 99%

Advances in predicting the prognosis of hepatocellular carcinoma recipients after liver transplantation

Wang

Zheng

2018

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most prevalent malignant tumors worldwide. Liver transplantation (LT) is known as a curative and therapeutic modality. However, the survival rates of recipients after LT are still not good enough because of tumor recurrence. To improve the survival rates of recipients after LT, identifying predictive factors for prognosis after LT and establishing a model assessing prognosis are very important to HCC patients. There has recently been a lot of clinical and basic research on recurrence and prognosis after LT. Progress has been made, especially in selection criteria for LT recipients and risk factors for predicting prognosis after LT. Hangzhou criteria, in line with China's high current incidence rate of primary liver, are first proposed by Chinese scholars of LT, and are accepted world-wide, and make an important contribution to the development of LT.

show abstract

“…Histopathological features such as microvascular invasion and tumor differentiation are well recognized predictive factors [16][17][18][19][20][21][22]. Thus, some trials have considered the inclusion of histological findings based on pretransplant needle biopsy in the patient selection criteria [20,23,24].…”

Section: Prognostic Factors Of Liver Transplantation For Hepatocellulmentioning

confidence: 99%

Expansion of the criteria for living donor liver transplantation for hepatocellular carcinoma

Lee

Suh

2016

Current Opinion in Organ Transplantation

View full text Add to dashboard Cite

show abstract

Predictive value of nodule size and differentiation in HCC recurrence after liver transplantation

Cited by 33 publications

References 43 publications

Accuracy of Pretransplant Imaging Diagnostic for Hepatocellular Carcinoma: A Retrospective German Multicenter Study

Accuracy of Pretransplant Imaging Diagnostic for Hepatocellular Carcinoma: A Retrospective German Multicenter Study

Advances in predicting the prognosis of hepatocellular carcinoma recipients after liver transplantation

Expansion of the criteria for living donor liver transplantation for hepatocellular carcinoma

Contact Info

Product

Resources

About